Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Gene Therapy R&D Market is projected to exceed US$3.50 billion by 2025, with anticipated robust growth through 2035. A comprehensive report reveals which organizations are leading the charge, highlighting their capabilities, developments, and commercial prospects-insights crucial for those aiming to capture new revenue streams and gain an enhanced understanding of the market dynamics.
Robust Gene Therapy Pipeline to Boost Growth
Cell and gene therapies (CGTs) are increasingly transitioning from research to clinical applications, particularly targeting specific diseases beyond the limited capabilities of small-molecule therapies. Among these, cancer remains the primary focus, dominating nearly half of the cell and gene therapies in trials.
CAR-T therapy-a combination of cell and gene therapy-stands out as a promising cancer treatment, leveraging modified immune cells to combat cancer. Despite its current niche availability, anticipated research advancements could broaden its application across various cancers. Notably, registered clinical trials in Q1 2025 soared to 2,155, up from 2,093 in Q1 2024, with oncology and rare diseases leading the gene therapy development pipeline.
Impact of US Trade Tariffs
Recent U.S. trade tariffs on pharmaceutical and biotechnological imports are expected to raise operational costs for gene therapy developers, predominantly due to potential supply chain disruptions and increased procurement expenses. Smaller organizations, with less financial resilience, are particularly vulnerable, possibly driving a trend towards domestic manufacturing to minimize tariff exposure. While potentially increasing regional autonomy, such shifts might hinder global collaborative networks that are pivotal to gene therapy innovation.
Key Questions Answered
- How is the gene therapy R&D market evolving?
- What are the primary drivers and constraints of the market?
- What submarket revenue forecasts extend to 2035?
- Who are the leading market players through 2035?
- Which geographical region is projected to dominate by 2035?
- What are the ongoing R&D projects among leading companies?
Report Highlights
- 357 pages, featuring 155 tables and 185 charts, offering exclusive insights.
- Identifies lucrative segments for targeted strategies.
- Analyzes global, regional, and national sales and growth metrics.
- Presents critical trends and revenue projections by competitors.
Forecasts and Market Analyses to 2035
- Revenue forecasting to 2035, including growth rates and market shares.
- Features business outlooks and developmental insights.
- Includes qualitative analyses, Porter's Five Forces, PEST Analysis, and recent industry advancements.
Disease Segments Covered: Cancer, Rare Diseases, Cardiovascular, Ophthalmic, Haematology, Neurological, Diabetes Mellitus, and Others.
Vector Techniques:
- Viral: Retrovirus, Adenovirus, AAV, Lentivirus, Others.
- Non-viral: Naked DNA, Gene Gun, Electroporation, Lipofection.
Participating Entities: Small/Medium Pharma & Biotech, Universities & Research Institutes, Government & Public Bodies, Big Pharma.
The report also offers regional revenue forecasts for North America, Europe, Asia Pacific, Latin America, and MEA, spanning several key national markets. It profiles leading companies in the Gene Therapy R&D Market, illustrating market potential and growth trajectories.
Leading Companies in the Gene Therapy R&D Sector
- American Gene Technologies
- Applied Genetic
- Astellas Pharma Inc.
- Bayer
- Benitec BioPharma
- Biogen
- Bluebird Bio
- Bristol Myers Squibb
- Calimmune, Inc. (CSL Behiring)
- Cellectis
- GenSight Biologics
- Gilead Lifesciences, Inc.
- GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.)
- Novartis AG
- OCUGEN, INC.
- Orchard Therapeutics
- Oxford Biomedica
- Pfizer, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Sanofi
- Sarepta Therapeutics, Inc.
- Spark Therapeutics (Subsidiary of Roche)
- Takeda Pharmaceutical Company Limited
- Taysha GTx
- Transgene
- UniQure N. V.
- VeonGen Therapeutics
- Voyager Therapeutics Inc.
- 3SBio
- Abeona
- Arctic Therapeutics
- Ayrmid
- Belief BioMed
- BlueRock Therapeutics LP
- Carlyle
- Chongqing Precision Biotech
- Coave Therapeutics
- Curocell
- EnPlusOne Biosciences
- EsoBiotec
- Garuda Therapeutics
- Helixmith
- Hubble Therapeutics
- Immunis
- Imunopharm
- Inceptor Bio
- Inhibrx, Inc.
- iOncologi
- MaxCyte
- MorphoSys AG
- Neumirna Therapeutics
- Novo Holdings
- Pacira BioSciences
- Precigen
- PulseSight Therapeutics
- Reata Pharmaceuticals, Inc.
- RegCell
- Regenxbio
- Replimune
- RheumaGen
- RhyGaze
- Rocket Pharmaceuticals
- SeQure
- SK Capital
- Skyline Therapeutics
- TargImmune Therapeutics
- Tebao Biotechnology
- Ultragenyx
For more information about this report visit https://www.researchandmarkets.com/r/s69b7w
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
